Resistance and Overcoming Resistance in Breast Cancer

Código QR

Resistance and Overcoming Resistance in Breast Cancer

Andrea Luque-Bolivar,1 Erika Pérez-Mora,1 Victoria Eugenia Villegas,2 Milena Rondón-Lagos1 1School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia, Tunja 150003, Colombia; 2Biology Program, Faculty of Natural Sciences, Universidad...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luque-Bolivar A, Pérez-Mora E, Villegas VE, Rondón-Lagos M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	breast cancer endocrine therapy chemotherapy resistance emerging treatments Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/7c1dfba0549d44dc9fb86bbd1ba05417
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Adjuvant systemic therapy in older women with breast cancer
por: Leone J, et al.
Publicado: (2016)

Genetic Influences in Breast Cancer Drug Resistance
por: Daniyal A, et al.
Publicado: (2021)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
por: Hyder T, et al.
Publicado: (2021)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Isabel Grote, et al.
Publicado: (2021)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Jiaojiao Suo, et al.
Publicado: (2021)

Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
por: Irina V. Kolyadina, et al.
Publicado: (2020)

The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
por: Yi-Kun Kang, et al.
Publicado: (2021)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021)

Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity
por: Sambi M, et al.
Publicado: (2017)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Dana S. Neel, et al.
Publicado: (2017)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel N, et al.
Publicado: (2017)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla S, et al.
Publicado: (2016)

Association of Endocrine Therapy and Dementia in Women with Breast Cancer
por: Thompson MR, et al.
Publicado: (2021)

Management of Early Breast Cancer at an Australian Cancer Centre During the Early Phase of COVID-19 Pandemic
por: Elissa J Zhang, et al.
Publicado: (2021)

Time to Adjuvant Chemotherapy and Its Predictors Among Women with Breast Cancer at the University of Gondar Compressive Specialized Hospital: A Retrospective Follow-Up Study
por: Zeleke Alem A, et al.
Publicado: (2020)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment
por: Perelmuter VM, et al.
Publicado: (2019)

Overcoming prostate cancer drug resistance with a novel organosilicon small molecule
por: Rui Zhao, et al.
Publicado: (2021)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Naiba Nabieva, et al.
Publicado: (2021)

Extreme Oncoplasty: Breast Conservation in Patients with Large, Multifocal, and Multicentric Breast Cancer
por: Savioli F, et al.
Publicado: (2021)

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
por: Melayshia McFadden, et al.
Publicado: (2021)

The Impact of AC and AC-T Chemotherapy’s Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study
por: Gadisa DA, et al.
Publicado: (2021)

Targeting stem cells in the realm of drug-resistant breast cancer
por: Dey P, et al.
Publicado: (2019)

Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy
por: Sales ACV, et al.
Publicado: (2020)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: Ana Julia Aguiar de Freitas, et al.
Publicado: (2021)

Interpretation of specification for breast cancer screening, early diagnosis, and treatment management in Chinese women
por: Fei Ma, et al.
Publicado: (2021)

Does the Presence of Cytokeratin Positive Individual Tumor Cells (N0(I+)) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation
por: Smith J, et al.
Publicado: (2021)

FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
por: Jakub Szymczyk, et al.
Publicado: (2021)

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice
por: Irina V. Kolyadina, et al.
Publicado: (2021)

Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
por: Hao Cui, et al.
Publicado: (2021)

Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer
por: Natalia I. Samaneva, et al.
Publicado: (2021)

Cryoablation In The Management Of Breast Cancer: Evidence To Date
por: Pusceddu C, et al.
Publicado: (2019)

Awareness and current knowledge of breast cancer
por: Akram,Muhammad, et al.
Publicado: (2017)

A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model
por: Soliman H, et al.
Publicado: (2015)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)